Pharmacogenetic biomarkers for the prediction of response to antiangiogenic treatment

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Antiangiogenic treatments have shown activity across multiple tumour types and in various settings. Despite having been approved on the basis of efficacy, the therapeutic index varies substantially in different settings for many of these agents. A major limitation is the current inability to personalise treatment a priori according to findings on measurement of a predictive biomarker. The roles of germline single-nucleotide polymorphisms have been investigated as potential biomarkers for antiangiogenic treatments. The rationale is founded on the understanding that the drugs target the vasculature rather than the tumour, which could mean that much of the variability is regulated by the host. Several single-nucleotide polymorphisms have been associated with differential outcomes and toxic effects in clinical trials. In this Review we provide an overview of available data with particular attention paid to the pitfalls and strengths of potential biomarkers. We also highlight continuing work and plans for confirmatory studies.

Original languageEnglish
JournalThe Lancet Oncology
Volume13
Issue number10
DOIs
StatePublished - Oct 2012

Fingerprint

Pharmacogenetics
Biomarkers
Single Nucleotide Polymorphism
Poisons
Neoplasms
Clinical Trials
Pharmaceutical Preparations
Therapeutics

ASJC Scopus subject areas

  • Oncology

Cite this

Pharmacogenetic biomarkers for the prediction of response to antiangiogenic treatment. / Schneider, Bryan; Shen, Fei; Miller, Kathy.

In: The Lancet Oncology, Vol. 13, No. 10, 10.2012.

Research output: Contribution to journalArticle

@article{4338d24b70604f0daa92326da9e575f1,
title = "Pharmacogenetic biomarkers for the prediction of response to antiangiogenic treatment",
abstract = "Antiangiogenic treatments have shown activity across multiple tumour types and in various settings. Despite having been approved on the basis of efficacy, the therapeutic index varies substantially in different settings for many of these agents. A major limitation is the current inability to personalise treatment a priori according to findings on measurement of a predictive biomarker. The roles of germline single-nucleotide polymorphisms have been investigated as potential biomarkers for antiangiogenic treatments. The rationale is founded on the understanding that the drugs target the vasculature rather than the tumour, which could mean that much of the variability is regulated by the host. Several single-nucleotide polymorphisms have been associated with differential outcomes and toxic effects in clinical trials. In this Review we provide an overview of available data with particular attention paid to the pitfalls and strengths of potential biomarkers. We also highlight continuing work and plans for confirmatory studies.",
author = "Bryan Schneider and Fei Shen and Kathy Miller",
year = "2012",
month = "10",
doi = "10.1016/S1470-2045(12)70275-9",
language = "English",
volume = "13",
journal = "The Lancet Oncology",
issn = "1470-2045",
publisher = "Lancet Publishing Group",
number = "10",

}

TY - JOUR

T1 - Pharmacogenetic biomarkers for the prediction of response to antiangiogenic treatment

AU - Schneider, Bryan

AU - Shen, Fei

AU - Miller, Kathy

PY - 2012/10

Y1 - 2012/10

N2 - Antiangiogenic treatments have shown activity across multiple tumour types and in various settings. Despite having been approved on the basis of efficacy, the therapeutic index varies substantially in different settings for many of these agents. A major limitation is the current inability to personalise treatment a priori according to findings on measurement of a predictive biomarker. The roles of germline single-nucleotide polymorphisms have been investigated as potential biomarkers for antiangiogenic treatments. The rationale is founded on the understanding that the drugs target the vasculature rather than the tumour, which could mean that much of the variability is regulated by the host. Several single-nucleotide polymorphisms have been associated with differential outcomes and toxic effects in clinical trials. In this Review we provide an overview of available data with particular attention paid to the pitfalls and strengths of potential biomarkers. We also highlight continuing work and plans for confirmatory studies.

AB - Antiangiogenic treatments have shown activity across multiple tumour types and in various settings. Despite having been approved on the basis of efficacy, the therapeutic index varies substantially in different settings for many of these agents. A major limitation is the current inability to personalise treatment a priori according to findings on measurement of a predictive biomarker. The roles of germline single-nucleotide polymorphisms have been investigated as potential biomarkers for antiangiogenic treatments. The rationale is founded on the understanding that the drugs target the vasculature rather than the tumour, which could mean that much of the variability is regulated by the host. Several single-nucleotide polymorphisms have been associated with differential outcomes and toxic effects in clinical trials. In this Review we provide an overview of available data with particular attention paid to the pitfalls and strengths of potential biomarkers. We also highlight continuing work and plans for confirmatory studies.

UR - http://www.scopus.com/inward/record.url?scp=84866849940&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866849940&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(12)70275-9

DO - 10.1016/S1470-2045(12)70275-9

M3 - Article

VL - 13

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 10

ER -